Close menu




April 22nd, 2021 | 10:40 CEST

SAP, wallstreet:online, Commerzbank - Money makes the world go round, get on board!

  • Investments
Photo credits: pixabay.com

Summit stormers and expectation management. While April has shown us its full range in weather in recent weeks, the stock market knows only one direction. New all-time highs in the stock markets reflect progress in fighting the pandemic as vaccination numbers rise. The bar for the just-started reporting season is very high this year. According to surveys, earnings in the S&P 500 are expected to increase by a whopping 24%. At the beginning of the year, expectations were much lower. Traditionally, the reporting season is opened by US banks in mid-April. Their figures exceeded market expectations by a wide margin, as the institutions were able to release provisions for loans. However, the fact that a share can be punished very quickly despite good figures was recently seen with Netflix. The following three companies will present their figures in the next few weeks. Who has the greatest short-term potential?

time to read: 4 minutes | Author: Carsten Mainitz
ISIN: DE0007164600 , DE000A2GS609 , DE000CBK1001

Table of contents:


    SAP SE - Strong performance

    Since mid-May, the SAP Group has released several good pieces of information. The Walldorf-based software company presents its first-quarter figures today, and shareholders will gather for the annual general meeting on May 12. A lot has happened since the share price plummeted to around EUR 90 in the fourth quarter of last year. At that time, the share was punished because of a more moderate medium-term outlook. Now the mood is brightening considerably. The share is currently trading at around EUR 116 again.

    In the middle of the month, a more optimistic company forecast for the cloud business surprised market participants. Based on the preliminary key data of Q1 and the increase of the guidance regarding the lower end of the target range for cloud and software revenues. As a result, several analysts commented positively. In our opinion, this makes it likely that price targets for the shares of Europe's largest software group will be raised in the near future. Also, in the middle of the month, SAP reported that it would spin off its financial services business. SAP is setting up a joint venture with the investment company Dediq for this purpose. The joint venture aims to "quickly establish itself as a force in the IT market." Dediq is investing a reasonable half billion euros, while SAP is contributing products, expertise and sales. The deal is expected to go through in Q3, subject to approval by the antitrust authorities. SAP will then hold 20% of the shares in the JV.

    The day before yesterday, there was news of a German-German partnership in the fight against the pandemic. Deutsche Telekom and SAP will build the technical infrastructure for the planned EU Covid certificate for more accessible travel in Europe. The EU announced that an initial contract had been signed with SAP and Telekom subsidiary T-Systems. The so-called "green certificate" is scheduled to go live at the end of the second quarter. It will allow Covid-relevant information such as test results, vaccinations and survived infections to be recorded and recognized throughout the EU. The EU states and the European Parliament still have to agree on the "green certificate" details. We keep our fingers crossed for all of us!

    WALLSTREET:ONLINE AG - Short breather

    In the first quarter, the brilliant price rally increased the Company's shares to almost EUR 30 by mid-February - a new all-time high. The figures for 2020 published at the end of February confirmed the Group's strong growth. The majority of analysts raised their price targets to around EUR 30, while a relatively sharp correction caused the share price to fall below EUR 18. Currently, the share price stands at EUR 21, valuing the Berlin-based Company just under EUR 300 million.

    As the leading independent financial portal operator in the German-speaking region, the Group has a strong market position in a high-margin business. However, the excellent share performance in recent months was based on the development and expansion of the transaction business via the 70% subsidiary wallstreet:online capital AG. The launch of Smartbroker took place via this at the end of 2019. Smartbroker is a so-called Neo Broker, enabling customers to trade for free or trade at very low conditions. Smartbroker differentiates itself by offering low or zero fees and a wide range of products. This combination is very well received by users, as measured by customer growth. The Group earns by receiving commissions from brokers or platforms for trades made. The reach of the financial portals also brings a USP into play that should significantly fuel the growth of Smartbroker in the future. Links to the portals already exist, and a trading app will be launched in the current year.

    Growth and expansion often require stronger personnel structures. For this reason, the Management Board has recently been strengthened once again. Matthias Hach became the Group's new CEO on March 1. Hach brings years of experience in online brokerage with several established players. Since April 1, the Executive Board has now grown to 5 people. Roland Nicklaus, who has been a member of the Supervisory Board for 13 years, takes over the function of CFO. The expanded team will thus be able to continue the success story.

    COMMERZBANK AG - Things are getting exciting

    Things are getting exciting at Commerzbank. On May 12, the Frankfurt-based bank will report on its performance in the first quarter. A few days later, on May 18, the Company will be inviting shareholders to its virtual Annual General Meeting. Given the excellent figures published by the major US banks a few days ago, anticipation also arose among German bank stocks. While anticipation is the best joy, this state of mind should sometimes be better used for profit-taking on the stock market. The past has shown far too often that German industry representatives lag miles behind the big players from the USA in terms of dynamism and profitability. Margins and return on equity are only a fraction of what the big players from overseas achieve. Therefore, it is not surprising that Commerzbank's shares are trading at a quarter of their book value, while those of its US competitors are trading at many times their book value.

    But the chart situation is also becoming increasingly exciting. Will the share succeed in sustainably surpassing the EUR 5.20 mark? Further suspense is in the air with the question of how the bank's restructuring is progressing and whether it will be possible to surprise positively at some point. After all, the book value is attractive, but profits are also needed. Whether that will be the case in 2022 or not until 2023 remains to be seen. Commerzbank announced that it would spend a total of around EUR 1.8 billion on restructuring as part of its 2024 strategy. It is questionable whether this budget will be sufficient.


    Conflict of interest

    Pursuant to §85 of the German Securities Trading Act (WpHG), we point out that Apaton Finance GmbH as well as partners, authors or employees of Apaton Finance GmbH (hereinafter referred to as "Relevant Persons") may in the future hold shares or other financial instruments of the mentioned companies or will bet on rising or falling on rising or falling prices and therefore a conflict of interest may arise in the future. conflict of interest may arise in the future. The Relevant Persons reserve the shares or other financial instruments of the company at any time (hereinafter referred to as the company at any time (hereinafter referred to as a "Transaction"). "Transaction"). Transactions may under certain circumstances influence the respective price of the shares or other financial instruments of the of the Company.

    Furthermore, Apaton Finance GmbH reserves the right to enter into future relationships with the company or with third parties in relation to reports on the company. with regard to reports on the company, which are published within the scope of the Apaton Finance GmbH as well as in the social media, on partner sites or in e-mails, on partner sites or in e-mails. The above references to existing conflicts of interest apply apply to all types and forms of publication used by Apaton Finance GmbH uses for publications on companies.

    Risk notice

    Apaton Finance GmbH offers editors, agencies and companies the opportunity to publish commentaries, interviews, summaries, news and etc. on news.financial. These contents serve information for readers and does not constitute a call to action or recommendations, neither explicitly nor implicitly. implicitly, they are to be understood as an assurance of possible price be understood. The contents do not replace individual professional investment advice and do not constitute an offer to sell the share(s) offer to sell the share(s) or other financial instrument(s) in question, nor is it an nor an invitation to buy or sell such.

    The content is expressly not a financial analysis, but rather financial analysis, but rather journalistic or advertising texts. Readers or users who make investment decisions or carry out transactions on the basis decisions or transactions on the basis of the information provided here act completely at their own risk. There is no contractual relationship between between Apaton Finance GmbH and its readers or the users of its offers. users of its offers, as our information only refers to the company and not to the company, but not to the investment decision of the reader or user. or user.

    The acquisition of financial instruments entails high risks that can lead to the total loss of the capital invested. The information published by Apaton Finance GmbH and its authors are based on careful research on careful research, nevertheless no liability for financial losses financial losses or a content guarantee for topicality, correctness, adequacy and completeness of the contents offered here. contents offered here. Please also note our Terms of use.


    Der Autor

    Carsten Mainitz

    Carsten Mainitz

    The native Rhineland-Palatinate has been a passionate market participant for more than 25 years. After studying business administration in Mannheim, he worked as a journalist, in equity sales and many years in equity research.

    About the author



    Related comments:

    Commented by Carsten Mainitz on October 14th, 2026 | 05:30 CEST

    Tungsten, Weapons and Growth: Almonty, Rheinmetall and Deutz Under Review. Is This an Opportunity in a Megatrend?

    • Tungsten
    • Raw materials
    • Critical raw materials
    • Geopolitics
    • Defence industry
    • Armaments
    • Military
    • Supply chains
    • Investments

    The stock market is not linear. Greed and fear, excessive optimism or excessive scepticism—all of these drive markets. Only the future will tell what is cheap or expensive today. The stocks mentioned above are at precisely this point. Secure supply chains, access to raw materials and defence readiness are high on the agenda of Western governments. These long-term trends play strongly into the hands of defence companies and raw material producers. Almonty, in particular, as a producer of the critical raw material tungsten, holds a leading position in the sector. Where do the greatest opportunities lie for investors now?

    Read

    Commented by Carsten Mainitz on October 14th, 2026 | 05:25 CEST

    Who Profits When Patents Expire? The Billion-Euro Race Between Formycon, Fresenius and Pfizer

    • Biosimilar
    • FDA
    • Milestone
    • Cancer therapy
    • Pharma
    • Patents
    • Investments

    When patent protection for high-revenue biopharmaceuticals expires, a billion-euro market for follow-on products emerges. Michael Sen, head of the German healthcare group Fresenius SE, cites an impressive figure. By 2035, this could generate around EUR 180 billion in revenue. In particular, biosimilars, biotechnologically produced follow-on medicines that are highly similar in composition to the original medicine and equivalent in quality, efficacy and safety, are forecast to grow significantly. Moreover, biosimilars can strengthen competition and reduce treatment costs. Formycon stands out as a pure play. The company recently reached a crucial milestone. The US Food and Drug Administration (FDA) accepted the marketing authorisation application, the first publicly known application of its kind, for FYB206, a biosimilar candidate to the cancer medicine Keytruda, for review. Keytruda generates around USD 32 billion in annual revenue, making it the world's highest-revenue medicine. Fresenius is strengthening its positioning in the biosimilar sector through an acquisition. Pfizer needs new growth drivers. Who is best positioned for the year-end rally?

    Read

    Commented by Matthias Schomber on October 12th, 2026 | 05:24 CEST

    Every Crisis Creates an Opportunity: Nordex Stumbles, Jungheinrich Struggles, and RE Royalties Looks to Have Found a Bottom

    • Investments
    • Trading Opportunity
    • Technical Analysis
    • Rebound

    When market participants suddenly lose their nerve, and industrial heavyweights like Jungheinrich plunge to new multi-year lows despite bulging order books, a key question for private investors, among others, is whether this is a dangerous crisis with further downside ahead or an attractive entry opportunity. Nordex, too, has recently struggled to build on its successes from earlier this year. The share is trapped in a consolidation phase and has now returned to its level from late February, when it broke out upwards on high volume and with a long green weekly candlestick. Is this an attractive entry point for investors desperately seeking stable, high-yield alternatives in the future-oriented renewable energy market? Find out why scepticism could prevail regarding well-known German names and why a pioneer in royalty financing could be on the verge of the next major share price surge following a technical “textbook pattern”.

    Read